3.6. Target Inhibition of JNK-cJUN-XRCC4 Pathway Sensitize Cisplatin-Resistant Ovarian Cancer to Cisplatin Treatment In Vitro and In Vivo. Here, XRCC4 is linked to ovarian cancer.